O

Oruka Therapeutics

Clinical-stage antibody therapies for psoriasis

Clinical Scientist - Clinical Development

Clinical Research OperationsConfirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • An advanced degree in life sciences, such as a PhD, PharmD, or related field.
  • Understanding of clinical trial methodologies and regulatory requirements.
  • Experience in clinical study design, data analysis, data review, and interpretation.
  • Three years of experience.
  • Good written and verbal communication skills.
  • Ability to work effectively in a collaborative, cross-functional environment.

Responsibilities

  • Contribute to developing clinical trial protocols, including patient selection criteria, study endpoints, and data collection methods.
  • Monitor clinical trial data at study sites to ensure adherence to protocols and good clinical practice guidelines.
  • Review, reconcile, and standardize data to ensure high-quality outputs.
  • Review clinical data to support assessment of the safety and efficacy of the investigational drug.
  • Support development of clinical documents required during clinical development, including Clinical Study Protocols, Investigator Brochures, and Clinical Study Reports.
  • Maintain knowledge of the therapeutic area, disease state, and potential drug effects.
  • Assess clinical data to help identify and analyze safety concerns and adverse events.
  • Stay current with relevant medical literature and clinical trial methodologies.
  • Conduct literature reviews as needed for focused scientific questions or documentation.
  • Work closely with clinical operations, regulatory affairs, medical affairs, biometrics, pre-clinical, and project management teams to ensure data integrity during clinical development.

About the Company

Oruka Therapeutics

Clinical-stage antibody therapies for psoriasis

Oruka Therapeutics develops antibody-based therapies for chronic skin diseases, focusing on plaque psoriasis and psoriatic arthritis. Its monoclonal antibodies, discovered and engineered by Paragon Therapeutics, are designed for longer dosing intervals to improve patient convenience. ORKA-001 targets IL-23p19 with an extended half-life that could allow dosing once or twice a year, while ORKA-002 targets IL-17A/F with dosing two to three times per year; both are in early-stage trials with Phase 2 planned for 2025–2026. The company aims to deliver higher skin clearance and durable remission to the large patient pool, pursuing commercialization after advancing through clinical trials; it entered public markets via a 2024 reverse merger with ARCA biopharma and raised over $475 million to fund operations through 2027.

Company size
11-50
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Oruka Therapeutics

See more jobs